drugset / Trial / NCT04901923
A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy Participants
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is to evaluate the safety, pharmacokinetics/pharmacodynamics (PK/PD), food-effect, and drug-drug interaction study of ACP-196 in healthy participants.
Timeline
- Start
- 2014-03-15
- Primary completion
- 2014-05-22
- Completion
- 2014-05-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acalabrutinib | Small molecule | 2.5 mg | Oral |
| Subject | Acalabrutinib | Small molecule | 5 mg | Oral |
| Subject | Acalabrutinib | Small molecule | 25 mg | Oral |
| Subject | Acalabrutinib | Small molecule | 50 mg | Oral |
| Subject | Acalabrutinib | Small molecule | 75 mg | Oral |
| Subject | Acalabrutinib | Small molecule | 100 mg | Oral |
| Subject | Itraconazole | Small molecule | 200 mg | — |
Indications
No indication recorded.